publication date: Feb. 7, 2020
NCI Trials
NCI Trials for Feb. 2020
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10336
Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/SÈzary Syndrome
NCI Center for Cancer Research
Miljkovic, Milos
(301) 250-5216
Phase II – 10315
A Phase 2 Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Yale University Cancer Center LAO
Tesfaye, Anteneh A.
(313) 576-8637
Phase II – A031803
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Alliance for Clinical Trials in Oncology
Woods, Michael Edward
708-216-3155
Phase II – EA1181
EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
ECOG-ACRIN Cancer Research Group
Tung, Nadine Muskatel
(617) 667-2176
Phase II – EA2187
A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
ECOG-ACRIN Cancer Research Group
Deming, Dustin Alan
(608) 265-1042
Phase II – EA6183
A Phase … Continue reading NCI Trials for Feb. 2020To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
